Products

99% Bulk Palbociclib Powder CAS 571190 -30-2

China 99% Bulk Palbociclib Powder CAS 571190-30-2, Find details about China Palbociclib, Palbociclib Use from 99% Bulk Palbociclib Powder CAS 571190-30-2

Model NO.
hupharma
Payment
Bitcoin/Wu/Mg/Wire Transfer
Minimum
10g
Delivery Time
1-3 Days
Shipping
Worldwide
Trademark
hupharma
Transport Package
Safe and Fast Delivery
Specification
10g, 100g, 1kg
Origin
China
HS Code
2937290090
Model NO.
hupharma
Payment
Bitcoin/Wu/Mg/Wire Transfer
Minimum
10g
Delivery Time
1-3 Days
Shipping
Worldwide
Trademark
hupharma
Transport Package
Safe and Fast Delivery
Specification
10g, 100g, 1kg
Origin
China
HS Code
2937290090
99% Bulk Palbociclib Powder CAS 571190-30-2

Product Name: Palbociclib
Synonyms: Palbociclib API;6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one;Pab Xilib;PD0332991; PD-0332991; PD 0332991;albociclib;Pyrido(2,3-D)pyrimidin-7(8H)-one, 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-;PD 0332991;OTAVA-BB 1115529;6-acetyl-8-cyclopentyl-5-Methyl-2-(5-(piperazin-1-yl)pyridin-2-ylaMino)pyrido[2,3-d]pyriMidin-7(8H)-one
CAS: 571190-30-2
MF: C24H29N7O2
MW: 447.53
EINECS: 810-186-2
Appearance: White Powder
Shipping: Safety and fast, guarantee delivery

Definition    ChEBI: A member of the class of pyridopyrimidines that is 2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7-one bearing additional methyl, acetyl and cyclopentyl substituents at positions 5, 6 and 8 respectively. It is used in combina ion with letrozole for the treatment of metastatic breast cancer.

Indications    Palbociclib (Ibrane(R), Pfizer), a selective CDK4 and CDK6 inhibitor, received accelerated approval from FDA in 2015 for women with estrogen receptor-positive and HER2-negative breast cancer in combination with letrozole.

Enzyme inhibitor    This orally active, non-ATP-competitive cyclin kinase-directed inhibitor (FW = 483.99 g/mol (mono-HCl); CASs = 827022-32-2 (mono- hydrochloride, 571190-30-2 (free base); Solubility: 10 mg/mL DMSO; 30 mg/mL Water; Formulation: Dissolved in sodium lactate buffer (50 mM, ® pH 4.0) ), also known as PD-0332991, Ibrance, and 6-acetyl-8-cyclopentyl- 5-methyl-2- (5- (piperazin-1-yl) pyridin-2-ylamino) pyrido[2,3-d]pyrimidin- 7 (8H) -one hydrochloride, targets Cdk-4 (Cyclin D1) and Cdk-6 (Cyclin D2), enzymes that participate in the so-called CDK4/6-retinoblastoma signaling pathway governing the cell-cycle restriction point. Palbociclib induces rapid G1 cell-cycle arrest in primary human myeloma cells. This agent also shows significant efficacy in a broad spectrum of human tumor xenografts in vivo, resulting in complete regression in some tumors with no evidence of acquired resistance or ability to circumvent the growth inhibitory properties of this agent. Ibrance received FDA approval in 2015 for combined use with letrozole to treat postmenopausal women with estrogen receptor- positive, (HER2) -negative advanced breast cancer as an initial endocrine- based therapy for metastatic disease. Cyclin Target Selectivity: Cdk1 (weak, if any), Cdk2 (weak, if any), Cdk3 (weak, if any), Cdk4 (IC50 = 11 nM), Cdk5 (weak, if any), Cdk6 (IC50 = 16 nM), Cdk7 (weak, if any), Cdk8 (weak, if any), Cdk9 (weak, if any), Cdk10 (weak, if any).


99% Bulk Palbociclib Powder CAS 571190-30-2

99% Bulk Palbociclib Powder CAS 571190-30-2

 

You Might Also Like